Claudia Avina
Research Subjects
Research Interests
Claudia Avina has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Aarthi Padmanabhan
Limbix Health, Inc, San Francisco, CA, United States
4 shared publications - Shana A. Hall
Clinical Affairs, Big Health Ltd., London, UK
4 shared publications - Daniella J. Furman
Limbix Health, Inc, San Francisco, CA, United States
3 shared publications - Jessica Lake
Limbix Health, Inc, San Francisco, CA, United States
3 shared publications - Elizabeth McCauley
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States
2 shared publications Emily E. Peake
2 shared publications
Latest Publications
- Open Access
- 9 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
A self-guided mobile app for symptoms of depression in adolescents: results of a randomized controlled trial (Preprint)
BACKGROUND Adolescent depression is a severe public health crisis exacerbated by extreme provider shortages and structural barriers to care. Self-guided digital therapeutics based on evidence-based psychotherapy offer a potentially scalable solution to bridge this expanding treatment gap, yet robust clinical trial evidence demonstrating their efficacy remains limited. OBJECTIVE This study aimed to evaluate the efficacy and safety of Spark, a 5-week, self-guided smartphone application based on behavioral activation protocols, as an adjunct treatment for symptoms of depression in adolescents and young adults. METHODS We conducted a decentralized, parallel-group, single-blind (investigator) randomized controlled trial across the United States. Participants aged 13–21 years with self-reported depression symptoms (8-item Patient Health Questionnaire [PHQ-8] score ≥ 5) under the care of a licensed healthcare provider were recruited online. They were randomized (1:1) to either the treatment arm (Spark app) or an active control arm (assessment-enhanced usual care [eUC] via a control app) for 5 weeks. Randomization was stratified by baseline severity and medication status. The primary outcome was depressive symptom severity measured via total PHQ-8 score at the post-intervention time point (week 5), analyzed using mixed-effects models for repeated measures (MMRM) in the intention-to-treat (ITT) population. Secondary outcomes included treatment response, remission, and 1-month follow-up durability. RESULTS The Spark group showed significantly greater reductions in depression symptoms compared to the control group at both the end of the intervention (p<0.001) and at the one-month follow-up (p=0.008). Spark participants were also nearly three times more likely to achieve treatment response (31.7% vs 11.6%), remission (24.9% vs 9.4%), and a minimal clinically important difference (40.5% vs 15.8%). Clinical benefits were consistent across age, baseline severity, and concurrent antidepressant use subgroups. The intervention was well-tolerated with no significant safety concerns, and fewer adverse events reported in the Spark arm (n=6) than in the usual care arm (n=16). CONCLUSIONS A self-guided, mobile app-based behavioral activation program is an effective, safe, and durable adjunct intervention for reducing depressive symptoms in adolescents. These findings support the deployment of validated digital therapeutics to provide immediate, scalable clinical care within a strained mental health infrastructure. CLINICALTRIAL ClinicalTrials.gov Registration Number: NCT05462652 https://clinicaltrials.gov INTERNATIONAL REGISTERED REPORT RR2-10.2196/48740
- 9 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA self-guided mobile app for symptoms of depression in adolescents: results of a randomized controlled trial (Preprint)
BACKGROUND Adolescent depression is a severe public health crisis exacerbated by extreme provider shortages and structural barriers to care. Self-guided digital therapeutics based on evidence-based psychotherapy offer a potentially scalable solution to bridge this expanding treatment gap, yet robust clinical trial evidence demonstrating their efficacy remains limited. OBJECTIVE This study aimed to evaluate the efficacy and safety of Spark, a 5-week, self-guided smartphone application based on behavioral activation protocols, as an adjunct treatment for symptoms of depression in adolescents and young adults. METHODS We conducted a decentralized, parallel-group, single-blind (investigator) randomized controlled trial across the United States. Participants aged 13–21 years with self-reported depression symptoms (8-item Patient Health Questionnaire [PHQ-8] score ≥ 5) under the care of a licensed healthcare provider were recruited online. They were randomized (1:1) to either the treatment arm (Spark app) or an active control arm (assessment-enhanced usual care [eUC] via a control app) for 5 weeks. Randomization was stratified by baseline severity and medication status. The primary outcome was depressive symptom severity measured via total PHQ-8 score at the post-intervention time point (week 5), analyzed using mixed-effects models for repeated measures (MMRM) in the intention-to-treat (ITT) population. Secondary outcomes included treatment response, remission, and 1-month follow-up durability. RESULTS The Spark group showed significantly greater reductions in depression symptoms compared to the control group at both the end of the intervention (p<0.001) and at the one-month follow-up (p=0.008). Spark participants were also nearly three times more likely to achieve treatment response (31.7% vs 11.6%), remission (24.9% vs 9.4%), and a minimal clinically important difference (40.5% vs 15.8%). Clinical benefits were consistent across age, baseline severity, and concurrent antidepressant use subgroups. The intervention was well-tolerated with no significant safety concerns, and fewer adverse events reported in the Spark arm (n=6) than in the usual care arm (n=16). CONCLUSIONS A self-guided, mobile app-based behavioral activation program is an effective, safe, and durable adjunct intervention for reducing depressive symptoms in adolescents. These findings support the deployment of validated digital therapeutics to provide immediate, scalable clinical care within a strained mental health infrastructure. CLINICALTRIAL ClinicalTrials.gov Registration Number: NCT05462652 https://clinicaltrials.gov INTERNATIONAL REGISTERED REPORT RR2-10.2196/48740
- Open Access
- 16 November 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48740
Assessing the Efficacy and Safety of a Digital Therapeutic for Symptoms of Depression in Adolescents: Protocol for a Randomized Controlled Trial
Background: Depression is a serious, prevalent, recurrent, and undertreated disorder in adolescents. Low levels of treatment seeking and treatment adherence in this age group, combined with a growing national crisis in access to mental health care, have increased efforts to identify effective treatment alternatives for this demographic. Digital health interventions for mental illness can provide cost-effective, engaging, and accessible means of delivering psychotherapy to adolescents. Objective: This protocol describes a virtual randomized controlled trial designed to evaluate the efficacy and safety of a self-guided, mobile app–based implementation of behavioral activation therapy, SparkRx, for the adjunct treatment of symptoms of depression in adolescents. Methods: Participants are recruited directly through web-based and print advertisements. Following eligibility screening and consenting, participants are randomly assigned to a treatment arm (SparkRx) or a control arm (assessment-enhanced usual care) for 5 weeks. The primary efficacy outcome, total score on the 8-item Patient Health Questionnaire (PHQ-8), is assessed at the end of the 5-week intervention period. Additional participant-reported outcomes are assessed at baseline, the postintervention time point, and 1-month follow-up. The safety of the intervention is assessed by participant report (and legal guardian report, if the participant is younger than 18 years) and by patterns of symptom deterioration on the PHQ-8, as part of a larger clinical safety monitoring protocol. The primary efficacy outcome, total PHQ-8 score at the postintervention time point, will be compared between SparkRx and enhanced usual care arms using mixed effect modeling, with baseline PHQ-8 and current antidepressant medication status included as covariates. Secondary efficacy outcomes, including the proportion of participants exhibiting treatment response, remission, and minimal clinically significant improvement (all derived from total PHQ-8 scores), will be compared between groups using chi-square tests. Symptom severity at 1-month follow-up will also be compared between arms. Planned subgroup analyses will examine the robustness of treatment effects to differences in baseline symptom severity (PHQ-8 score <15 or ≥ 15) and age (younger than 18 years and older than 18 years). The primary safety outcome, the number of psychiatric serious adverse events, will be compared between trial arms using the Fisher exact test. All other adverse events will be presented descriptively. Results: As of May 2023, enrollment into the study has concluded; 223 participants were randomized. The analysis of the efficacy and safety data is expected to be completed by Fall 2023. Conclusions: We hypothesize that the results of this trial will support the efficacy and safety of SparkRx in attenuating symptoms of depression in adolescents. Positive results would more broadly support the prospect of using accessible, scientifically validated, digital therapeutics in the adjunct treatment of mental health disorders in this age range. Trial Registration: ClinicalTrials.gov NCT05462652; https://clinicaltrials.gov/study/NCT05462652 International Registered Report Identifier (IRRID): DERR1-10.2196/48740
- 16 November 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48740
Open AccessAssessing the Efficacy and Safety of a Digital Therapeutic for Symptoms of Depression in Adolescents: Protocol for a Randomized Controlled Trial
Background: Depression is a serious, prevalent, recurrent, and undertreated disorder in adolescents. Low levels of treatment seeking and treatment adherence in this age group, combined with a growing national crisis in access to mental health care, have increased efforts to identify effective treatment alternatives for this demographic. Digital health interventions for mental illness can provide cost-effective, engaging, and accessible means of delivering psychotherapy to adolescents. Objective: This protocol describes a virtual randomized controlled trial designed to evaluate the efficacy and safety of a self-guided, mobile app–based implementation of behavioral activation therapy, SparkRx, for the adjunct treatment of symptoms of depression in adolescents. Methods: Participants are recruited directly through web-based and print advertisements. Following eligibility screening and consenting, participants are randomly assigned to a treatment arm (SparkRx) or a control arm (assessment-enhanced usual care) for 5 weeks. The primary efficacy outcome, total score on the 8-item Patient Health Questionnaire (PHQ-8), is assessed at the end of the 5-week intervention period. Additional participant-reported outcomes are assessed at baseline, the postintervention time point, and 1-month follow-up. The safety of the intervention is assessed by participant report (and legal guardian report, if the participant is younger than 18 years) and by patterns of symptom deterioration on the PHQ-8, as part of a larger clinical safety monitoring protocol. The primary efficacy outcome, total PHQ-8 score at the postintervention time point, will be compared between SparkRx and enhanced usual care arms using mixed effect modeling, with baseline PHQ-8 and current antidepressant medication status included as covariates. Secondary efficacy outcomes, including the proportion of participants exhibiting treatment response, remission, and minimal clinically significant improvement (all derived from total PHQ-8 scores), will be compared between groups using chi-square tests. Symptom severity at 1-month follow-up will also be compared between arms. Planned subgroup analyses will examine the robustness of treatment effects to differences in baseline symptom severity (PHQ-8 score <15 or ≥ 15) and age (younger than 18 years and older than 18 years). The primary safety outcome, the number of psychiatric serious adverse events, will be compared between trial arms using the Fisher exact test. All other adverse events will be presented descriptively. Results: As of May 2023, enrollment into the study has concluded; 223 participants were randomized. The analysis of the efficacy and safety data is expected to be completed by Fall 2023. Conclusions: We hypothesize that the results of this trial will support the efficacy and safety of SparkRx in attenuating symptoms of depression in adolescents. Positive results would more broadly support the prospect of using accessible, scientifically validated, digital therapeutics in the adjunct treatment of mental health disorders in this age range. Trial Registration: ClinicalTrials.gov NCT05462652; https://clinicaltrials.gov/study/NCT05462652 International Registered Report Identifier (IRRID): DERR1-10.2196/48740
- Open Access
- 4 May 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Assessing the Efficacy and Safety of a Digital Therapeutic for Symptoms of Depression in Adolescents: Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND Depression is a serious, prevalent, recurrent, and undertreated disorder in adolescents. Low levels of treatment seeking and treatment adherence in this age group, combined with a growing national crisis in access to mental health care, have increased efforts to identify effective treatment alternatives for this demographic. Digital health interventions for mental illness can provide cost-effective, engaging, and accessible means of delivering psychotherapy to adolescents. OBJECTIVE This protocol describes a virtual randomized controlled trial designed to evaluate the efficacy and safety of a self-guided, mobile app–based implementation of behavioral activation therapy, SparkRx, for the adjunct treatment of symptoms of depression in adolescents. METHODS Participants are recruited directly through web-based and print advertisements. Following eligibility screening and consenting, participants are randomly assigned to a treatment arm (SparkRx) or a control arm (assessment-enhanced usual care) for 5 weeks. The primary efficacy outcome, total score on the 8-item Patient Health Questionnaire (PHQ-8), is assessed at the end of the 5-week intervention period. Additional participant-reported outcomes are assessed at baseline, the postintervention time point, and 1-month follow-up. The safety of the intervention is assessed by participant report (and legal guardian report, if the participant is younger than 18 years) and by patterns of symptom deterioration on the PHQ-8, as part of a larger clinical safety monitoring protocol. The primary efficacy outcome, total PHQ-8 score at the postintervention time point, will be compared between SparkRx and enhanced usual care arms using mixed effect modeling, with baseline PHQ-8 and current antidepressant medication status included as covariates. Secondary efficacy outcomes, including the proportion of participants exhibiting treatment response, remission, and minimal clinically significant improvement (all derived from total PHQ-8 scores), will be compared between groups using chi-square tests. Symptom severity at 1-month follow-up will also be compared between arms. Planned subgroup analyses will examine the robustness of treatment effects to differences in baseline symptom severity (PHQ-8 score <15 or ≥ 15) and age (younger than 18 years and older than 18 years). The primary safety outcome, the number of psychiatric serious adverse events, will be compared between trial arms using the Fisher exact test. All other adverse events will be presented descriptively. RESULTS As of May 2023, enrollment into the study has concluded; 223 participants were randomized. The analysis of the efficacy and safety data is expected to be completed by Fall 2023. CONCLUSIONS We hypothesize that the results of this trial will support the efficacy and safety of SparkRx in attenuating symptoms of depression in adolescents. Positive results would more broadly support the prospect of using accessible, scientifically validated, digital therapeutics in the adjunct treatment of mental health disorders in this age range. CLINICALTRIAL ClinicalTrials.gov NCT05462652; https://clinicaltrials.gov/study/NCT05462652 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48740
- 4 May 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAssessing the Efficacy and Safety of a Digital Therapeutic for Symptoms of Depression in Adolescents: Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND Depression is a serious, prevalent, recurrent, and undertreated disorder in adolescents. Low levels of treatment seeking and treatment adherence in this age group, combined with a growing national crisis in access to mental health care, have increased efforts to identify effective treatment alternatives for this demographic. Digital health interventions for mental illness can provide cost-effective, engaging, and accessible means of delivering psychotherapy to adolescents. OBJECTIVE This protocol describes a virtual randomized controlled trial designed to evaluate the efficacy and safety of a self-guided, mobile app–based implementation of behavioral activation therapy, SparkRx, for the adjunct treatment of symptoms of depression in adolescents. METHODS Participants are recruited directly through web-based and print advertisements. Following eligibility screening and consenting, participants are randomly assigned to a treatment arm (SparkRx) or a control arm (assessment-enhanced usual care) for 5 weeks. The primary efficacy outcome, total score on the 8-item Patient Health Questionnaire (PHQ-8), is assessed at the end of the 5-week intervention period. Additional participant-reported outcomes are assessed at baseline, the postintervention time point, and 1-month follow-up. The safety of the intervention is assessed by participant report (and legal guardian report, if the participant is younger than 18 years) and by patterns of symptom deterioration on the PHQ-8, as part of a larger clinical safety monitoring protocol. The primary efficacy outcome, total PHQ-8 score at the postintervention time point, will be compared between SparkRx and enhanced usual care arms using mixed effect modeling, with baseline PHQ-8 and current antidepressant medication status included as covariates. Secondary efficacy outcomes, including the proportion of participants exhibiting treatment response, remission, and minimal clinically significant improvement (all derived from total PHQ-8 scores), will be compared between groups using chi-square tests. Symptom severity at 1-month follow-up will also be compared between arms. Planned subgroup analyses will examine the robustness of treatment effects to differences in baseline symptom severity (PHQ-8 score <15 or ≥ 15) and age (younger than 18 years and older than 18 years). The primary safety outcome, the number of psychiatric serious adverse events, will be compared between trial arms using the Fisher exact test. All other adverse events will be presented descriptively. RESULTS As of May 2023, enrollment into the study has concluded; 223 participants were randomized. The analysis of the efficacy and safety data is expected to be completed by Fall 2023. CONCLUSIONS We hypothesize that the results of this trial will support the efficacy and safety of SparkRx in attenuating symptoms of depression in adolescents. Positive results would more broadly support the prospect of using accessible, scientifically validated, digital therapeutics in the adjunct treatment of mental health disorders in this age range. CLINICALTRIAL ClinicalTrials.gov NCT05462652; https://clinicaltrials.gov/study/NCT05462652 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48740
- 1 February 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 61 (9) , 1119-1130
Trajectories of Treatment Response and Nonresponse in Youth at High Risk for Suicide
- 1 February 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 61 (9) , 1119-1130
Trajectories of Treatment Response and Nonresponse in Youth at High Risk for Suicide
- 1 September 2021
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 60 (9) , 1105-1115.e4
Dialectical Behavior Therapy for Suicidal Self-Harming Youth: Emotion Regulation, Mechanisms, and Mediators
- 1 September 2021
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 60 (9) , 1105-1115.e4
Dialectical Behavior Therapy for Suicidal Self-Harming Youth: Emotion Regulation, Mechanisms, and Mediators
- 1 September 2000
- Published by Elsevier in Research in Developmental Disabilities
- Vol. 21 (5) , 377-391
A review of “noncontingent” reinforcement as treatment for the aberrant behavior of individuals with developmental disabilities
- 1 September 2000
- Published by Elsevier in Research in Developmental Disabilities
- Vol. 21 (5) , 377-391
A review of “noncontingent” reinforcement as treatment for the aberrant behavior of individuals with developmental disabilities